ABSTRACT
Li-Fraumeni syndrome (LFS) is a rare, autosomal dominant, hereditary cancer predisposition disorder. In Brazil, the p.R337H TP53 founder mutation causes the variant form of LFS, Li-Fraumeni-like syndrome. The occurrence of cancer and age of disease onset are known to vary, even in patients carrying the same mutation, and several mechanisms such as genetic and epigenetic alterations may be involved in this variability. However, the extent of involvement of such events has not been clarified. It is well established that p53 regulates several pathways, including the thymine DNA glycosylase (TDG) pathway, which regulates the DNA methylation of several genes. This study aimed to identify the DNA methylation pattern of genes potentially related to the TDG pathway (CDKN2A, FOXA1, HOXD8, OCT4, SOX2, and SOX17) in 30 patients with germline TP53 mutations, 10 patients with wild-type TP53, and 10 healthy individuals. We also evaluated TDG expression in patients with adrenocortical tumors (ADR) with and without the p.R337H TP53 mutation. Gene methylation patterns of peripheral blood DNA samples assessed by pyrosequencing revealed no significant differences between the three groups. However, increased TDG expression was observed by quantitative reverse transcription PCR in p.R337H carriers with ADR. Considering the rarity of this phenotype and the relevance of these findings, further studies using a larger sample set are necessary to confirm our results.
Subject(s)
Humans , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Biological Products/adverse effects , Antirheumatic Agents/therapeutic use , Biological Products/therapeutic use , Evidence-Based Medicine/methods , Neoplasms/chemically induced , Opportunistic Infections/chemically induced , Practice Guidelines as Topic , Risk Assessment/methods , Tumor Necrosis Factor-alpha/antagonists & inhibitorsABSTRACT
Human epidermal growth factor receptor 2 (HER2) has been evaluated in breast cancer patients to identify those most likely to benefit from herceptin-targeted therapy. HER2 amplification, detected in 20-30% of invasive breast tumors, is associated with reduced survival and metastasis. The most frequently used technique for evaluating HER2 protein status as a routine procedure is immunohistochemistry (IHC). HER2 copy number alterations have also been evaluated by fluorescence in situ hybridization (FISH) in moderate immunoexpression (IHC 2+) cases. An alternative procedure to evaluate gene amplification is chromogenic in situ hybridization (CISH), which has some advantages over FISH, including the correlation between HER2 status and morphological features. Other methodologies have also been used, such as silver-enhanced in situ hybridization (SISH) and quantitative real-time RT-PCR, to determine the number of HER2 gene copies and expression, respectively. Here we will present a short and comprehensive review of the current advances concerning HER2 evaluation in human breast cancer.
Subject(s)
Female , Humans , Breast Neoplasms/genetics , /genetics , In Situ Hybridization, Fluorescence , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Chromogenic Compounds , Gene Amplification , Immunohistochemistry , Real-Time Polymerase Chain Reaction , Sensitivity and Specificity , Biomarkers, Tumor/geneticsABSTRACT
Loss of Y-chromosome has been correlated with older age in males. Furthermore, current evidence indicates that Y-chromosome loss also occurs in several human tumors, including head and neck carcinomas. However, the association between Y nullisomy and the occurrence of neoplasias in elderly men has not been well established. In the present study, the association between Y-chromosome loss and head and neck carcinomas was evaluated by comparison to cells from peripheral blood lymphocytes and normal mucosa of cancer-free individuals matched for age using dual-color fluorescence in situ hybridization. Twenty-one patients ranging in age from 28 to 68 years were divided into five-year groups for comparison with 16 cancer-free individuals matched for age. The medical records of all patients were examined to obtain clinical and histopathological data. None of the patients had undergone radiotherapy or chemotherapy before surgery. In all groups, the frequency of Y-chromosome loss was higher among patients than among normal reference subjects (P < 0.0001) and was not age-dependent. These data suggest that Y-chromosome loss is a tumor-specific alteration not associated with advanced age in head and neck carcinomas.
Subject(s)
Adult , Aged , Humans , Male , Middle Aged , Chromosome Deletion , Carcinoma, Squamous Cell/genetics , Chromosomes, Human, Y/genetics , Head and Neck Neoplasms/genetics , Age of Onset , Case-Control Studies , In Situ Hybridization, Fluorescence , KaryotypeABSTRACT
Três leiomiomas uterinos humanos foram cultivados e analisados citogeneticamente. Embora o número modal estivesse na regiäo diplóide, todas as neoplasias apresentaram hiperdiploidia. Um dos casos apresentou 27% das células na regiäo hipertriplóide-hipertraplóide. As alteraçöes numéricas mais frequentes foram monossomias envolvendo os cromossomos 20 (3 casos) e 2, 7, 18 (2 casos cada) e um caso apresentou polissomias de todos os cromossomos (variando de trissomia a pentassomia). Um caso apresentou um grande anel cromossômico semelhante ao cromossomo 1 e um marcador com o rearranjo: t(2;12) (2qter - 2q14-15 - 12 pter). O significado das alteraçöes citogenéticas em tumores benignos ainda está por ser determinada